(American Society of Hematology) Adolescents and young adults with acute leukemia have a survival advantage if they receive treatment at a pediatric cancer center versus an adult center, according to a new study.

Related Links:

Pediatric Blood&Cancer, EarlyView.

Source: Pediatric Blood and CancerCategory: Cancer & Oncology Authors:

CONCLUSIONS: These data provide the first national, population-based estimates of fertility documentation for AYA cancer patients in Australia. Documentation of fertility-related discussions was poor, with higher rates observed in hospitals with greater experience of treating AYA patients.
PMID: 29784137 [PubMed – in process]

Source: European Journal of Oncology NursingCategory: Nursing Authors: Tags: Eur J Oncol Nurs Source Type: research

(American Society of Clinical Oncology) In a federally funded, randomized phase III clinical trial performed by the Children’s Oncology Group (COG), 90 percent of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84 percent were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors.

Authors: Simioni C, Zauli G, Martelli AM, Vitale M, Ultimo S, Milani D, Neri LM
Abstract
A decreased physical fitness has been reported in patients and survivors of acute lymphoblastic leukemia (ALL). This is influenced by the negative effects of the disease and by the treatments of childhood cancer. In the past, children were advised to recover in bed, and to take as much relax as possible. Nowadays, it is considered that too much immobility may result in a further decrease of physical fitness and functioning. Exercise training for ALL children has frequently been reported to improve physical fitness and the well-…

Source: OncotargetCategory: Cancer & Oncology Tags: Oncotarget Source Type: research

Pediatric Blood&Cancer, EarlyView.

Source: Pediatric Blood and CancerCategory: Cancer & Oncology Authors:

AbstractPurpose of reviewAdolescent and Young Adult (AYA) Oncology is a relatively new field encompassing research in the unique pathophysiology, clinical care, and psychosocial issues facing patients between the ages of 15 and 40 with cancer. About 100,000 of the approximately 1.5 million people diagnosed annually with cancer in the USA are in this age range. This chapter will review notable new developments in the care of adolescents and young adults with acute lymphoblastic leukemia (ALL) within the last 3  years.Recent findingsThe preponderance of data favors the treatment of AYA ALL patients with pediatric-inspir…

Pediatric Blood&Cancer, EarlyView.

This article analyzes the tangible and intangible impacts involved in the experience of young adults diagnosed with a long-term illness, namely Acute Myeloid Leukemia. It follows on from broader research, inspired by the Phenomenology of Alfred Schutz. The data were obtained through in-depth interviews with four young adults, aged between 20 and 28, who were in the maintenance phase of cancer treatment between November 2013 and January 2014 in the State of Mato Grosso. The results focus on striking aspects of the impacts of the experience during the process of becoming aware of the illness in which the diagnosis provoked f…

Adoptive transfer of chimeric antigen receptor (CAR) T cells is a promising treatment for cancer patients. Recently, one CD19 targeted CAR-T cell product has been approved for pediatric and young adults with B cell acute lymphblastic leukemia (B-ALL) and another approval is imminent for aggressive B cell lymphomas. However, commercial viability of CAR-T immunotherapy remains a challenge due to costly, lengthy, and labor-intensive productions.

Source: Biology of Blood and Marrow TransplantationCategory: Hematology Authors: Source Type: research

(UT Southwestern Medical Center) A historic study involving researchers from UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center demonstrates the effectiveness of CAR-T therapy, which uses genetically modified immune cells to treat acute lymphoblastic leukemia in children and young adults.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image